Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Solid Tumor”

177 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 177 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Early research (Phase 1)Active Not RecruitingNCT04511871
What this trial is testing

A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Who this might be right for
Solid TumorGastric CancerBreast Cancer+2 more
Shanghai PerHum Therapeutics Co., Ltd. 12
Testing effectiveness (Phase 2)Looking for participantsNCT04585750
What this trial is testing

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Who this might be right for
Advanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more
PMV Pharmaceuticals, Inc 300
Testing effectiveness (Phase 2)Looking for participantsNCT07462650
What this trial is testing

Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticAdenocarcinoma of Colon
Beijing Biotech 48
Very early researchLooking for participantsNCT06822998
What this trial is testing

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
HighField Biopharmaceuticals Corporation 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Early research (Phase 1)Study completedNCT01245205
What this trial is testing

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 28
Early research (Phase 1)UnknownNCT04189211
What this trial is testing

A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients

Who this might be right for
HER2-Positive Solid Tumors
Bio-Thera Solutions 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05593094
What this trial is testing

Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHER2-positive Breast Cancer
Hoffmann-La Roche 210
Testing effectiveness (Phase 2)WithdrawnNCT05234606
What this trial is testing

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Who this might be right for
Urothelial CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer+2 more
Silverback Therapeutics
Testing effectiveness (Phase 2)Ended earlyNCT04172597
What this trial is testing

Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Who this might be right for
Breast CancerColorectal CancerSolid Tumor+1 more
Spectrum Pharmaceuticals, Inc 1
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Early research (Phase 1)Study completedNCT03099174
What this trial is testing

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Who this might be right for
NeoplasmsBreast Neoplasms
Boehringer Ingelheim 133
Early research (Phase 1)Looking for participantsNCT06500052
What this trial is testing

BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Who this might be right for
Esophageal CancerGastric CancerPancreatic Cancer+2 more
Sichuan Baili Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)UnknownNCT05512780
What this trial is testing

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer

Who this might be right for
Solid Tumor
Hebei Medical University Fourth Hospital 30
Early research (Phase 1)UnknownNCT05810103
What this trial is testing

DP303c in Patients With HER2-positive Advanced Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT07122063
What this trial is testing

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd. 266
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Next Page